DeepScribe vs Heidi Health
Both claim conversation support in roughly 110 languages, so for once in this lane language settles nothing. The grades settle plenty: DeepScribe holds an A on clinical evidence against Heidi's C, on the strength of a 98.8 KLAS Emerging Company Spotlight score and a published oncology study, and an A on EHR depth against Heidi's C, writing discrete fields bidirectionally where Heidi's push to chart is reported as gated to upper tiers. What Heidi holds is reach and transparency: a reported 190 countries and more than 200 specialties, published pricing from a free tier, and a platform expanding into cited decision support through Heidi Evidence, where DeepScribe sells through enterprise sales with no trial. If your failure mode is complex specialty documentation, oncology above all, with evidence a committee will accept, start with DeepScribe. If your failure mode is geography, a price you can see, or a caseload spread across many specialties rather than deep in one, start with Heidi, and confirm the BAA and write back tier gates before contracting.
- Specialty depth over specialty count: oncology as its center of gravity with a reported 40 percent of US cancer care visits and tuned models for six further specialties, against Heidi's breadth claim of more than 200 specialties without published depth in any one.
- The grades split hard in its favor: an A on clinical evidence against Heidi's C, on a 98.8 KLAS Emerging Company Spotlight score and a published oncology study, and an A on EHR depth against Heidi's C, writing discrete fields bidirectionally where Heidi's push to chart is reported as gated to upper tiers.
- Coding lives in the note: HCC, CPT, and ICD-10 suggestions built in, with chart context read before the visit and structured data written after.
- Geography and reach: a reported 190 countries and more than 200 specialties on 2.5 million consults a week, where DeepScribe's center of gravity is US specialty care.
- You need a price without a sales call: a free tier with unlimited transcription and a published Clinician tier at $150 per user per month billed annually, where DeepScribe runs enterprise sales with no self serve signup and no trial.
- The platform is expanding under you: Heidi Evidence surfaces cited clinical decision support from BMJ, NICE, and HealthPathways at the point of care, and Heidi Comms coordinates patient calls, on a company that raised a $65 million Series B in late 2025.
Side-by-Side
| Axis | D DeepScribe |
H Heidi Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | — |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Volume and coverage figures for both vendors are vendor published, including both language claims, DeepScribe's oncology share, and Heidi's weekly consult count. DeepScribe's KLAS scores are buyer survey based, and the Emerging Company Spotlight is a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane. Heidi's clinical evidence grades C, with third party review candid that multi problem visits document less reliably than single problem encounters and no accuracy study against ground truth retrieved. Two Heidi tier gates matter for US buyers: the organization wide Business Associate Agreement and EHR write back are both reported as available only from the Practice tier upward; Heidi's pricing was also restructured in February 2026 with sources conflicting on some tier amounts. Heidi's pricing is published; DeepScribe publishes none, with third party estimates of $350 to $500 per provider per month recorded as unconfirmed.